George Grunberger

Summary

Publications

  1. ncbi request reprint The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    Diabetes Metab Res Rev 23:56-62. 2007
  2. doi request reprint Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA
    J Diabetes 5:241-53. 2013
  3. doi request reprint Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    Postgrad Med 125:79-90. 2013
  4. doi request reprint Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    J Diabetes 5:110-7. 2013
  5. doi request reprint The need for better insulin therapy
    G Grunberger
    Grunberger Diabetes Institute, Department of Internal Medicine, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Bloomfield Hills, MI 48302, USA
    Diabetes Obes Metab 15:1-5. 2013
  6. doi request reprint Quo vadis nateglinide? Ten-year perspective
    George Grunberger
    Grunberger Diabetes Institute, 43494 Woodward Avenue, Bloomfield Hills, MI 48302, USA
    Expert Opin Pharmacother 12:2097-106. 2011
  7. ncbi request reprint Fetuin-null mice are protected against obesity and insulin resistance associated with aging
    Suresh T Mathews
    Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Biochem Biophys Res Commun 350:437-43. 2006
  8. ncbi request reprint Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes
    Marcelo F Di Carli
    Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA
    J Am Coll Cardiol 41:1387-93. 2003
  9. pmc The C-peptide signaling
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA
    Exp Diabesity Res 5:25-36. 2004
  10. ncbi request reprint Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene
    Suresh T Mathews
    Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Diabetes 51:2450-8. 2002

Detail Information

Publications16

  1. ncbi request reprint The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    Diabetes Metab Res Rev 23:56-62. 2007
    ..In the current double-blind study, obese patients with type 2 diabetes were recruited for a 3-month study to examine the health effects of a new dietary fibre, FBCx...
  2. doi request reprint Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA
    J Diabetes 5:241-53. 2013
    ..Both classes of agents address the so called "incretin defect" in patients with T2DM. ..
  3. doi request reprint Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    Postgrad Med 125:79-90. 2013
    ..Glycemic control is improved by preventing the DPP-4-mediated degradation of incretin hormones, with a resulting increase in insulin secretion and inhibition of glucagon secretion...
  4. doi request reprint Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA
    J Diabetes 5:110-7. 2013
    ..Importantly, the use of these agents is not associated with hypoglycemia or weight gain...
  5. doi request reprint The need for better insulin therapy
    G Grunberger
    Grunberger Diabetes Institute, Department of Internal Medicine, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Bloomfield Hills, MI 48302, USA
    Diabetes Obes Metab 15:1-5. 2013
    ....
  6. doi request reprint Quo vadis nateglinide? Ten-year perspective
    George Grunberger
    Grunberger Diabetes Institute, 43494 Woodward Avenue, Bloomfield Hills, MI 48302, USA
    Expert Opin Pharmacother 12:2097-106. 2011
    ..It is thus timely to review our experience with this agent...
  7. ncbi request reprint Fetuin-null mice are protected against obesity and insulin resistance associated with aging
    Suresh T Mathews
    Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Biochem Biophys Res Commun 350:437-43. 2006
    ..Taken together, this study suggests that the absence of fetuin may contribute to the improvement of insulin sensitivity associated with aging...
  8. ncbi request reprint Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes
    Marcelo F Di Carli
    Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA
    J Am Coll Cardiol 41:1387-93. 2003
    ..We sought to determine the differences in coronary microvascular function between patients with type 1 (insulin-deficient) and type 2 (insulin-resistant) diabetes mellitus (DM)...
  9. pmc The C-peptide signaling
    George Grunberger
    Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA
    Exp Diabesity Res 5:25-36. 2004
    ..Lacking a purified C-peptide receptor, we also demonstrate C-peptide effects on distinct elements of the insulin signal transduction pathways...
  10. ncbi request reprint Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene
    Suresh T Mathews
    Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Diabetes 51:2450-8. 2002
    ....
  11. ncbi request reprint Coronary vascular dysfunction in premenopausal women with diabetes mellitus
    Marcelo F Di Carli
    Department of Medicine, Wayne State University School of Medicine, Detroit, Mich, USA
    Am Heart J 144:711-8. 2002
    ..The objective of this study was to investigate the effect of diabetes on coronary vascular function in premenopausal women...
  12. ncbi request reprint Hippocampal neuronal apoptosis in type 1 diabetes
    Zhen Guo Li
    Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Brain Res 946:221-31. 2002
    ..The data also suggest that this is at least in part related to impaired insulin and/or IGF activities...
  13. ncbi request reprint Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes
    Graham T McMahon
    Brigham and Women s Hospital, Division of Nuclear Medicine, 75 Francis Street, Boston, MA 02115, USA
    Diabetes Care 28:1145-50. 2005
    ..We sought to determine whether pioglitazone, an insulin-sensitizing peroxisome proliferator-activated receptor (PPAR)-gamma agonist, improves cardiac endothelial function in individuals with type 2 diabetes...
  14. pmc Type 1 diabetic neuropathy and C-peptide
    Anders A F Sima
    Department of Pathology, Wayne State University, Detroit, Michigan 48201, USA
    Exp Diabesity Res 5:65-77. 2004
    ..Large-scale food and drug administration (FDA)-approved clinical trials are necessary to make this natural substance available to the globally increasing type 1 diabetic population...
  15. ncbi request reprint Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force
    Paul S Jellinger
    Endocr Pract 13:260-8. 2007
  16. ncbi request reprint Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control
    Vivian Fonseca
    Tulane University Medical Center, New Orleans, Louisiana, USA
    Diabetes Care 26:1685-90. 2003
    ..To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic control and on postprandial glucose and insulin levels in patients with type 2 diabetes...